MedPath

Different Doses of IVIG for Kawasaki Disease

Phase 3
Completed
Conditions
Kawasaki Disease
Interventions
Drug: IVIG (1g/kg,once)
Drug: IVIG (1g/kg,twice)
Drug: IVIG (2g/kg.once)
Registration Number
NCT02439996
Lead Sponsor
Children's Hospital of Fudan University
Brief Summary

The objective of this study is to investigate the effect of different doses of intravenous immunoglobulin (IVIG) (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease (KD) in a multicentre, prospective,randomised trial.

Detailed Description

Kawasaki disease is an acute febrile illness recognized most often in young children. Coronary abnormality is the most serious complication preventable with intravenous immunoglobulin (IVIG) administration. Various treatment regimens of IVIG have been reported.The optimal administrative doses of IVIG deserves more observations.We will conduct a multicenter, randomized, prospective trial to determine the effect of different doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease. The KD children will be randomly assigned to three groups and were given different IVIG regimen (1g/kg once, 1g/kg twice, 2g/kg once)as initial treatment. Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. The primary outcome is the duration of fever subsided and the incidence of coronary artery lesions .

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
404
Inclusion Criteria
  • Individual patient's medical file data confirmed the diagnosis of KD using the 5th revised edition of diagnostic criteria for KD, issued by the Japan Kawasaki Disease Research Committee at the 7th International Kawasaki Disease Symposium in 2002.
  • the patients aged from 1 months to 12 years old.
  • All included patients required to sign an informed consent form.
  • the patients didn't receive treatment before.
Exclusion Criteria
  • The patients with the application of hormone or other immunosuppressive agents;
  • The patients didn't want to signed informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IVIG(1g/kg,once)IVIG (1g/kg,once)The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
IVIG(1g/kg,twice)IVIG (1g/kg,twice)The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
IVIG(2g/kg.once)IVIG (2g/kg.once)The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
Primary Outcome Measures
NameTimeMethod
Duration of fever subsided to normal after initial IVIG finished36 hours after IVIG finished

Hours of fever subsided to normal after initial IVIG finished

incidence of coronary artery lesions(CAL) after IVIG finishedstart from IVIG finished, ended by the end of 2 weeks

incidence of coronary artery lesions(CAL) after IVIG finished diagnosed by echocardiography

Secondary Outcome Measures
NameTimeMethod
total medical cost for KD treatment during hospital stayestimated about up to 10 days, start from admission,ended by discharge

record the hospital duration of every patient and the medical expenses for KD

incidence of coronary artery lesions(CAL) after IVIG finishedstart from IVIG finished, ended by the end of 6 month

incidence of coronary artery lesions(CAL) after IVIG finished diagnosed by echocardiography and coronary atery angiogram

Total dose of immunoglobin used for every patientestimated about up to 10 days, start from admission,ended by discharge

Total dose of immunoglobin used for every patient

total frequency (%) of severe adverse eventsestimated about up to 10 days, start from admission,ended by discharge

Severe adverse events included death, infection or exacerbation, heart failure, allergic reaction, etc

Trial Locations

Locations (1)

Children Hospital of Fudan University

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath